Analysis of the CHA2DS2-VASc score in patients with inadequate anticoagulation control
10.15343/0104-7809.202145318326
Keywords:
Atrial Fibrillation. Warfarin. Aging.Abstract
Among the tools for assessing the risk of thromboembolic events, the CHA2DS2-VASc score stands out, which contributes to the identification of patients that are eligible for the use of anticoagulant therapy, which is a great aid in thromboembolic prophylaxis. The present study aims to characterize patients with inadequate control of anticoagulation according to their CHA2DS2-VASc score. Information was collected from patients being followed up at an anticoagulation clinic associated with a teaching hospital in Minas Gerais. Patients accompanied at the clinic between August and December 2017, taking warfarin for at least 180 days, with a chronic indication for anticoagulation, and with at least values from two results of the International Normalized List (INR) test were included. 434 patients were identified and 202 with inadequate anticoagulation control. For patients with inadequate control, the CHA2DS2-VASc was calculated, which is performed by the sum of risk factor scores for thromboembolic events. Patients were classified as low (0 points), moderate (1 point), or high (≥ 2 points) risk. An association was also made between the score and variables that characterize the context of the patients, such as the municipality of residence and the target therapeutic range of the INR. It is noteworthy that 107 (53.0%) had hypertension; 96 (47.5%) had peripheral arterial, coronary or aortic disease; 62 (30.7%) had a previous stroke; and 27 (13.4%) had diabetes. A considerable percentage of patients with CHA2DS2-VASc ≥ 2 (n = 191; 94.5%) was identified, which indicates a high risk for the occurrence of thromboembolic events and reinforces the importance of adequate anticoagulant pharmacotherapy. Regarding the association between demographic characteristics and the results of the CHA2DS2-VASc score, an association was identified between the CHA2DS2-VASc score and city of residence (p<0.05), with no statistical significance being identified between the CHA2DS2-VASc score and the INR target therapeutic range (p>0.05).
Downloads
References
2. Chugh SS, Roth GA, Gillum RF, Mensah GA. Global burden of atrial fibrillation in developed and developing nations. Glob Heart. 2014:9(1); 113-9.
3. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001:285(18); 2370-5.
4. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014:129(8); 837-47.
5. William E, Cayley JR. Self-monitoring and self-management of anticoagulation therapy. Am Fam Physician. 2011:84(3); 266-68.
6. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008:133(Suppl 6); 160S-98S.
7. Cruciol-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics. 2006:61(6); 515-20.
8. Costa JM, Pimento MC, Groia RCS, Costa MA, Antunes MISS, Martins MAP. Mensurações do Time in Therapeutical Range em pacientes em uso de anticoagulante oral. Rev Bras Farm Hosp Serv Saúde. 2016:7(1); 13-16.
9. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijins HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010:137(2); 263-72.
10. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993:69(3); 236-9.
11. Camm AJ, Kirchhof P, Lip GY, Schotten U, Sevelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010:12(10); 1360-420.
12. World Health Organization. World report on ageing and health. WHO [Internet]. 2015. Disponível em: http://www.who.int/ ageing/events/world-report-2015-launch/en/.
13. Veras R. [Envelhecimento populacional e as informações de saúde do PNAD: demandas e desafios contemporâneos. Introdução]. Cad Saude Publica. 2007:23(10); 2463-6.
14. Kelly DT. Disease burden of cardiovascular disease in the elderly. Coron Artery Dis. 1997:8(10); 667-9.
15. Bonneux L, Barendregt JJ, Meeter K, Bonsel GJ, van der Maas PJ. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health. 1994:84(1); 20-8.
16. Correia M, Silva MR, Matos I, Magalhães R, Lopes JC, Ferro JM, et al. Prospective community-based study of stroke in Northern Portugal: incidence and case fatality in rural and urban populations. Stroke. 2004:35(9); 2048-53.
17. Lee WC, Lamas GA, Balu S, Spalding J, Wang Q, Pashos CL. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ. 2008:11(2); 281-98.
18. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011:4(3); 313-20.
19. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014:130(23); 2071-104.
20. Lang A, Macdonald M, Marck P, Toon L, Griffin M, Easty T, et al. Seniors managing multiple medications: using mixed methods to view the home care safety lens. BMC Health Serv Res. 2015:15; 548.
21. Lip GY. The CHA2DS2-VASc score for stroke risk stratification in patients with atrial fibrillation: a brief history. Eur Heart J [Internet]. 2019:40(7). Disponível em: https://doi.org/10.1093/eurheartj/ehv431
22. Stopa SR, Malta DC, Monteiro CN, Szwarcwald CL, Goldbaum M, Cesar CLG. Acesso e uso de serviços de saúde pela população brasileira, Pesquisa Nacional de Saúde 2013. Rev Saude Publica. 2017:51; Supl 1:3s
23. Nunes BP, Flores TR, Garcia LP, Chiavegatto Filho ADP, Thumé E, Facchini LA. Tendência temporal da falta de acesso aos serviços de saúde no Brasil, 1998-2013. Epidemiol Serv Saude. 2016:25(4); 777-787.
24. Joundi RA, Cipriano LE, Sposato LA, Saposnik G. Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis. Stroke. 2016:47(5); 1364-7
25. Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA. 2015:314(10); 1030-8.
26. Martins MAP, Costa JM, Mambrini JVM, Ribeiro ALP, Benjamin EJ, Brant LCC, et al. Health literacy and warfarin therapy at two anticoagulation clinics in Brazil. Heart. 2017:103(14); 1089-95.
